With the exception of P18 who was treated with hydroxyurea because investigations revealed thrombocytosis with a JAK2 V614F point mutation, second-line agents were initiated because of severity of L-HES disease manifestations and/or requirement for high-dose maintenance OCS therapy. This evidence concerns the gene JAK2 and thrombocytosis disease.